is generally a plasma/blood drug concentration that lies between the minimum effect concentration (MEC) and minimum toxic concentration (MTC). Cephalexin is a semisynthetic antibiotic derived from cephalosporin C and is almost completely absorbed from the gastrointestinal tract, with a bioavailability of 95%. Cephalexin has a half-life of around 1.1 h. [3] [4] [5] To maintain therapeutic range, the drug should be administered 3-4 times a day, which leads to sawtooth kinetics and resulting in ineffective therapy. [6] Addressing this problem, we attempted to formulate extended release tablets of cephalexin, which can provide constant effective drug level for 6 h, based on calculations considering pharmacokinetic parameters.
MATERIALS AND METHODS

Materials
The chemicals used in the experiment were: Cephalexin monohydrate (Aurobindo Pharma Ltd., Hyderabad, India), microcrystalline cellulose PH102 (Weiming Industries, China), lactose anhydrous (DMV-Fonterra Excipients, Germany), hydroxypropyl methyl cellulose (HPMC) 15cps and HPMC K15M (Feicheng Ruitai Fine chemicals, China), colloidal silicon dioxide (Degussa India Pvt. Ltd., Mumbai, India), magnesium stearate (Ferro Corporation, USA), Sporidex AF 375 (Ranbaxy laboratories Pvt. Ltd., Gurgaon, India). All the other reagents used were of analytical grade. [7] Accurately weighed quantities of drug and excipients were passed through sieve no: 20 and 40, respectively. Drug and excipients (excluding lubricant) were added in geometric proportions and mixed thoroughly for 15 min. The blend was mixed finally with lubricant to get the granules of cephalexin monohydrate. The flow properties of granules were characterized in terms of angle of repose, Carr's index and Hausner's ratio. The bulk density and tapped density were determined using USP bulk density apparatus (Veego Industries, Mumbai, India). The data summarized in Table 1 .
Methods
Preparation and evaluation of cephalexin monohydrate granules
Formulation of cephalexin matrix tablets using direct compression method [8] The prepared granules of cephalexin monohydrate were compressed in 15 × 8.5 mm punches of 27 station rotary tablet compression machine (CMB4D Cadmach, Ahmadabad, India). The formulae for batches F1-F9 are shown in Tables 2 and 3 . [8, 9] The prepared cephalexin matrix tablets were evaluated for thickness, hardness, friability, uniformity of weight and drug content. The thicknesses of tablets were measured using vernier caliper (Aerospace, China). Hardness of tablets was tested using a validated modified dial type hardness tester (Shivani Scientific Industries, Mumbai, India). Friability of tablets was determined by using Roche Friabilator (Electrolabs, Banglore, India). The drug content of each batch was determined as per USP assay of cephalexin using high performance liquid chromatography (HPLC; SCL-10AVP, Shimadzu Corporation, Japan). [10] The results are shown in Table 4 .
Evaluation of tablet properties
In vitro drug release study
The drug release studies of cephalexin matrix tablets were performed using dissolution testing apparatus USP type I (Basket type; Electrolabs, Banglore, India). The dissolution testing was performed using 900 ml of 0.01 N HCl for the 1 st h and phosphate buffer, pH 6.8, from 2 nd h to 6 th h at 37 ± 0.5°C temperature and speed 100 rpm for 6 h. A sample (5 ml) of the solution was withdrawn from the dissolution testing apparatus at 1 st , 2 nd , 4 th and 6 th h and the samples were replaced with fresh dissolution medium. The samples were filtered through a 0.45 μm membrane filter and diluted to a suitable concentration with the corresponding medium. Absorbance of these solutions was measured at 262 nm using UV-1650 spectrophotometer (Shimadzu Corporation, Japan). [11] The in vitro drug release specification was 20-40% at 1 st h, 40-60% at 2 nd h, 60-80% at 4 th h and >80% at 6 th h, determined from theoretical drug release and dissolution pattern of the marketed product. The in vitro drug release data is a singular term which shows a single set of grouped data shown in Table 5 and also graphically represented in Figures 1 and 2 .
Experimental design [12, 13] A 3 2 full factorial design was adopted and the amount of polymers, HPMC K15M (X 1 ) and HPMC K15cps (X 2 ), were taken as independent variables and cumulative percentage drug release at 1 st h (Y 1 ), 2 nd h (Y 2 ) and 4 th h (Y 3 ) was taken as dependent variables as shown in Table 6 . The factors were studied at three levels (−1, 0, +1) indicating low, medium and high, respectively, as represented in Multiple regression analysis [12] The use of regression analysis in 3 2 factorial design generates polynomial equations for different models, with interacting terms and regression coefficients, useful in evaluating the responses. The software generates two models, particularly, full model (non-significant terms included) and reduced model (excluding non-significant terms). In the full model study, the responses were analyzed using the quadratic equation below:
where Y is the response evaluated, b 0 is the arithmetic mean response of 9 runs and b i is the estimated coefficient of X i . The main effects (X 1 and X 2 ) represent the average result of changing one factor at a time from its low to high value. The interaction term (X 1 X 2 ) shows how the response changes when two factors are simultaneously changed. The polynomial terms (X 1 2 and X 2 2 ) were included to investigate nonlinearity.
In the reduced model study, the non-significant terms in the quadratic equation are removed using backward regression procedure to generate a reduced model which is more important in studying the influence of factors on the responses evaluated. The value and sign of regression coefficient (b i ) indicates the magnitude of influence of the particular term on the response. The regression coefficients give the average change in a response when the particular factor is changed by a unit, when all the other terms remain constant. A positive sign on the regression coefficient indicates the factor has a positive effect on the response and negative sign indicates a negative effect.
ANOVA study [13] The software performs the individual analysis of responses and calculates the sum of squares (SS), mean square (MS), Fischer's ratio (F statistics) and P value. The F statistics and P value give the significance level of each term, considering the null hypothesis (H 0 ) is true. The terms with a P value less than 0.05 are considered significant at a level of significance α = 0.05. When the F value obtained is greater than the critical F value from the F distribution table, the factor becomes significant and the null hypothesis is rejected. [14] The similarity in drug release pattern of the marketed product (Sporidex AF 375) and the formulation developed was compared by similarity factor (f 2 ) determination. The two products are said to be similar if the value of f 2 lies between 50 and 100. The similarity factor and a similarity testing have been recommended for dissolution profile comparison in the Food and Drug Administration (FDA)'s Guidance for Industry. The f 2 is calculated using the formula given below:
Comparison of dissolution profiles
where R t is the percentage of reference product dissolved at a specified time, T t is the percentage of test product dissolved at a specified time, and n is the number of sampling points.
Pharmacokinetic study [14, 15] To study the release kinetics, the data obtained from in vitro drug release studies were plotted in various kinetic models as follows: where Q i and K i stand for the amount of drug release and kinetic release constant, respectively. M t /M α indicates the fractional drug release and "n" is the diffusional exponent which gives the mechanism of drug release. When n<0.5, the drug diffuses through the polymeric matrix by a Fickian (case I) diffusion mechanism. For 0.5 < n<1, an anomalous (non-Fickian) mechanism occurs; n=1 indicates a zero-order (case II) and n>1 indicates non-Fickian super case II release mechanism.
The plots were drawn using Microsoft excel 2007 and the regression equations were obtained for each plot. The linearity of the plots was obtained from the value of regression coefficient (R). The model with the highest linearity (R value approaching unity) was chosen as the best fit kinetic model.
Accelerated stability studies [16] Short-term accelerated stability studies were performed on the optimized tablet formulations of blister packed cephalexin extended release tablets. The tablets were subjected to stability studies at 40°C/75% relative humidity (RH) in a stability chamber (Servewell Instrument Pvt. Ltd., Bengaluru, India) for a period of 1 month. Initial evaluation of the tablets was done, and at the end of first month the tablets were again analyzed for their physical appearance, water content and in vitro drug release profile.
RESULTS AND DISCUSSION
The bulk density of granules was found to be between 0.54 ± 0.32 and 0.58 ± 0.41 g/cm 
Multiple regression analysis
Backward regression analysis technique was used to generate the best fit models for the analyzed responses. nd and 4 th h as the coefficients carry a negative sign. It also indicates that the HPMC 15cps increases the drug release from the tablet during 1 st and 2 nd h as the coefficients carry a positive sign and the polymer has no effect at the 4 th h as it is a non-significant term.
ANOVA (Analysis of variance) studies
The ANOVA of 1 st h from Table 8 indicates that both HPMC K15M and HPMC 15cps are significant terms as the F values are above the critical F values, thus making the P values less than 0.05 (threshold level). Thus, the null hypothesis H 0 is rejected and the alternate hypothesis that the two polymers used significantly influence the rate of drug release from the cephalexin matrix tablets is found to be true.
The ANOVA of 2
nd h from Table 9 shows that both HPMC K15M and HPMC 15cps are significant terms, indicating that both the polymers influence the rate of drug release at the 2 nd h from the cephalexin matrix tablets and the alternate hypothesis holds good in this case.
The ANOVA of 4 th h from Table 10 indicates that the only term significant is HPMC K15M, and HPMC 15cps was found to have no influence in the 4 th h release from cephalexin matrix tablets. The polymer HPMC 15cps with a low viscosity is found to have rate-controlling effect only in the initial hours and HPMC K15M with a higher viscosity grade has rate-controlling effects even in the 4 th h.
The 3D response surface plots give a representation of 
Pharmacokinetic report
The kinetic summary from Table 11 reveals that cephalexin extended release tablets follow zero-order kinetics as the regression coefficients approach unity, indicating that the drug release is independent of drug concentration. The n values from Korsemeyer-Peppas model show that the drug release pattern follows mainly Fickian diffusion mechanism, but erosion too plays a significant role as the formulations F3, F6, F9 show n values above 0.5. The Higuchi plots also show good linearity, indicating that the drug release is proportional to the square root of time and the drug release is at a slower rate as the distance of diffusion increases.
Comparison of dissolution profiles
The similarity factor (f 2 ) shown in Table 12 indicates that F3 gave the most similar dissolution profile to that of the marketed product. Thus, F3 was determined as the optimized product and is preferred for scale-up batches. The drug release pattern of optimized product F3 and theoretical release pattern were compared to determine the similarity and is shown in Figure 6 . The graph shows good correlation between the dissolution profiles of marketed product F3 and the theoretical release pattern.
Accelerated stability study report
The accelerated stability study report shown in Table 13 reveals that the formulation has not undergone any physical or chemical degradation during the period. There are no significant differences in the in vitro drug release and the drug content of the optimized formulation. 
